Alessio Molfino is an expert in Nutrition at Sapienza University of Rome (Italy). As of October 2026, ScienceLeadR ranks Alessio Molfino in the top 1% of experts worldwide for Cachexia and Body Weight, and in the top 1% of experts in Italy for Weight Loss. Alessio Molfino has authored 233 publications, the most recent in 2026, and is an investigator in 3 clinical trials. SLR score: 762 (community average: 125). How the SLR is computed.

LeadR Profile

Alessio Molfino Sapienza University of Rome Italy
762 ScienceLeadR Reputation 762
Network Map

Nutrition

Subspecialties: Critical Care - Oncology - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026

Source: PubMed

Sapienza University of Rome

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 233

Citations

Citations: 3 355 1st author: 105 Last author: 32 Unique author: 1


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Integrated miRNA-cytokine profiling reveals a molecular signature of cachexia in patients with chronic heart failure.
PMID 42853063 — cytokines, growth, heart failure, heart, micrornas, growth differentiation factor 15, phenotype, heart failure, diastolic, heart failure, systolic, cachexia
ESC Heart Fail20260
Differential Associations of Lipopolysaccharide, Soluble NOX2-Derived Peptide, and Hydrogen Peroxide with Adiposity and Muscularity in Adults on Maintenance Hemodialysis.
PMID 42792195 — endotoxemia, peroxides, stress, physiological, body composition, oxidative stress, adiposity, maintenance, hydrogen peroxide, lipopolysaccharides
Antioxidants (Basel)20260
Circulating MicroRNAs Reflect Body Composition Features in Newly Diagnosed Breast Cancer.
PMID 42653104 — muscles, breast neoplasms, micrornas, neoplasms, body composition, breast
Int J Mol Sci20260
Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry.
PMID 42642609 — diabetes mellitus, registries, kidney diseases, sodium-glucose transporter 2 inhibitors, chronic disease, heart diseases, internal medicine, heart, cardiovascular diseases, prescriptions, kidney, aged
Intern Emerg Med20260
Clinically recognized sepsis in older adults admitted to medical wards: patient characteristics and hospital outcomes from the REPOSI register.
PMID 42635922 — mortality, internal medicine, hospital mortality, sepsis, multimorbidity, therapeutics, infections
Intern Emerg Med20260

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3

By status:

Completed 2
Recruiting 1

By type:

Observational 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 6

LeadR Networks

Main global connection map